Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sirtuin 2 (SIRT2) is a member of the sirtuin family of proteins, which are NAD+-dependent deacetylases and ADP-ribosyltransferases. It plays roles in cellular regulation, metabolism, aging, and disease. It is primarily cytosolic but also found in the nucleus during certain cell cycle phases. SIRT2 exerts multiple regulatory functions, including NAD+-dependent lysine deacetylase activity and mono ADP-ribosyltransferase activity. It regulates microtubule dynamics, myelination control, gluconeogenesis, chromatin compaction, and DNA damage response. SIRT2 modulates autophagy/mitophagy and is implicated as both a tumor suppressor or promoter depending on context. It is a potential therapeutic target for age-related disorders including cancer/metabolic syndrome/neurodegeneration.
Binding NAD+ at its catalytic core, deacetylating substrate lysines via an ADPR peptidyl-imidate intermediate, and releasing nicotinamide from NAD+, transferring acetyl group from substrate to form O-acetyl ADP ribose plus deacetylated protein product.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sirtuin 2 (None).